We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ADVANCED INSTRUMENTS

Advanced Instruments designs, manufactures and markets laboratory products for the clinical, food and dairy, microbio... read more Featured Products: More products

Download Mobile App




Automated Cerebrospinal Fluid Cell Counter Granted USA Diagnostics Marketing Approval

By LabMedica International staff writers
Posted on 18 Jul 2016
The [U.S.] Food and Drug Administration has granted diagnostic use marketing approval (510(k) clearance) for an automated cell counting system that accurately quantifies the low number of cells found in cerebrospinal fluid (CSF).

The Advanced Instruments, Inc., (Norwood, MA, USA) patented GloCyte Automated Cell Counter System delivers highly accurate and precise total nucleated cell (TNC) and red blood cell (RBC) results using a novel combination of fluorescence technology, highly specific reagents, and an intelligent counting algorithm. More...
It provides accurate cell counts at clinically relevant low levels and reduces valuable time spent counting those more difficult specimens.

Analyses preformed with the GloCyteSystem require only 30 microliters of sample per test. The instrument uses disposable test cartridges ensuring no sample carryover and easy disposal, and it includes built-in quality control.

The GloCyte instrument, which should be available in the USA from September 2016, is complemented by the 510(k) approved GloCyte Low and High Level Controls.

“To date, there has not been a way to provide dependable low cell counts,” said John Coughlin, president and CEO of Advanced Instruments. “We use a novel combination of fluorescence, microscopy with digital image analysis principles, highly specific reagents, and an intelligent counting algorithm to provide accurate and precise cell counts. We are very excited as this marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results.”

Related Links:
Advanced Instruments



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.